12:00 AM
 | 
Dec 20, 2001
 |  BC Extra  |  Company News

Neurogen, Aventis CRF1 deal

AVE licensed exclusive worldwide rights to NRGN's corticotrophin releasing factor ( CRF1) antagonist compounds, for...

Read the full 57 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

$50 USD
More Info >